Search results
Showing 1 to 3 of 3 results for voxelotor
Voxelotor for treating haemolytic anaemia caused by sickle cell disease (TA981)
NICE has withdrawn this guidance. Pfizer has informed the Medicines and Healthcare products Regulatory Agency (MHRA) that the product is being withdrawn. The recall notification is being shared with all healthcare professionals. No new people will start taking voxelotor in the UK. Healthcare professionals should discuss alternative treatment options with people currently having voxelotor.
More than 20 pieces of draft and final guidance on a range of medicines and medical conditions were published during the pre-election period.
Around 4,000 people with sickle cell disease could benefit from a new treatment recommended by NICE
Improved deal signals NICE recommendation of sickle cell treatment voxelotor.